Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccines 98

Vaccines Immunization Communication 98

Pharmaceutical Technology

DECEMBER 5, 2022

With the establishment of this Translational Science Hub, Queensland is set to become an international messenger ribonucleic acid (mRNA) vaccine hub. With an initial focus on enchaining mRNA technology and developing a vaccine for Chlamydia, the research at the hub is anticipated to commence in the first quarter of next year.

Vaccines 98

Vaccines Communication Immunization 98

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccines 64

Vaccines Pharmaceutical Companies Pharmaceutical Companies FDA 64

Pharmaceutical Technology

DECEMBER 1, 2022

A clinical-stage biopharmaceutical firm, Liminatus focuses on the development of new therapies for cancer that utilises the immune system of the body to detect and fight cancer cells. The GCC Vaccine is being analysed in Phase II clinical trials. The boards of directors of both companies have granted approval for the merger.

Immunization 52

Immunization Vaccines Communication 52

Pharmaceutical Technology

MARCH 24, 2023

Since the first human administration of the Bacillus Calmette-Guérin vaccine in 1921, no one has been able to successfully follow the vaccine’s path to become the next approved vaccine to tackle tuberculosis (TB). However, as the TB-related death toll remains high, the global need for another vaccine is steadily rising.

Vaccines 64

Vaccines Health and Personal Care Stores Immunization Communication 64

Pharmaceutical Technology

MARCH 21, 2023

Source: GlobalData Pharmaceutical Intelligence Center Clinical trial catalysts In late January, AC Immune released positive interim results from the Phase I/II trial (NCT05462106) studying the company’s vaccine in patients with prodromal Alzheimer’s disease.

Packaging 59

Packaging FDA Vaccines Labelling 59

Pharmaceutical Technology

FEBRUARY 20, 2023

The capabilities of Viroclinics and DDL allowed us to rapidly test repurposed drugs, new vaccines and antiviral solutions for the prevention and treatment of patients affected by COVID-19 in 2020. A lot of unique assays have already been added to a common portfolio and colleagues from both businesses are working well together.

Vaccines 52

Vaccines Communication Immunization 52